Erdheim-chester disease

Rheumatic Disease Clinics of North America

Volumn 39, Issue 2, 2013, Pages 299-311

  Haroche, Julien ^a,b   Arnaud, Laurent ^a,b   Cohen Aubart, Fleur ^a,b   Hervier, Baptiste ^a,b   Charlotte, Frédéric ^a   Emile, Jean François ^c   Amoura, Zahir ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

BRAF; Erdheim Chester disease; Histiocytosis; Interferon ; Langerhans cell histiocytosis

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; C REACTIVE PROTEIN; CD68 ANTIGEN; CLADRIBINE; IMATINIB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGINTERFERON ALPHA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; T6 ANTIGEN; TECHNETIUM 99M; VEMURAFENIB;

BONE DISEASE; BONE PAIN; BONE SCINTISCANNING; BONES OF THE LEG AND FOOT; BRAF GENE; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CRANIAL NERVE PARALYSIS; DIABETES INSIPIDUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ENDOCRINE DISEASE; ERDHEIM CHESTER DISEASE; EXOPHTHALMOS; FOLLOW UP; GENE MUTATION; HEART DISEASE; HEART INFARCTION; HISTIOCYTE; HISTOPATHOLOGY; HYDRONEPHROSIS; HYPERGONADOTROPISM; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; INCIDENCE; ISOTOPE LABELING; LANGERHANS CELL HISTIOCYTOSIS; LOW DRUG DOSE; LUNG DISEASE; MORTALITY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OSTEOSCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RETROPERITONEAL FIBROSIS; REVIEW; SENSORY DYSFUNCTION; SEX RATIO; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; TH1 CELL; VALVULAR HEART DISEASE; XANTHELASMA;

BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM DISEASES; DIAGNOSIS, DIFFERENTIAL; ENZYME INHIBITORS; ERDHEIM-CHESTER DISEASE; HISTIOCYTES; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOLOGIC FACTORS; INDOLES; INTERFERON-ALPHA; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84876699920     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.02.011     Document Type: Review

References (58)

1. Chester W. über Lipoidgranulomatose. Virchows Archiv für Pathologische Anatomie und Physiologie und für Klinische Medizin 1930, 279:561-602. [in German].
2. Adam Z., Koukalova R., Sprlakova A., et al. Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review. Vnitr Lek 2011, 57:576-589. [in Czech].
3. Haroche J., Arnaud L., Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012, 24(1):53-59.
4. Arnaud L., Hervier B., Neel A., et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011, 117:2778-2782.
5. Haroche J., Amoura Z., Dion E., et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) 2004, 83:371-392.
6. Veyssier-Belot C., Cacoub P., Caparros-Lefebvre D., et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 1996, 75:157-169.
7. Brower A.C., Worsham G.F., Dudley A.H. Erdheim-Chester disease: a distinct lipoidosis or part of the spectrum of histiocytosis?. Radiology 1984, 151:35-38.
8. Tsai J.W., Tsou J.H., Hung L.Y., et al. Combined Erdheim-Chester disease and Langerhans cell histiocytosis of skin are both monoclonal: a rare case with human androgen-receptor gene analysis. J Am Acad Dermatol 2010, 63:284-291.
9. Wang K.H., Cheng C.J., Hu C.H., et al. Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai-Dorfman disease. Br J Dermatol 2002, 147:770-774.
10. Balink H., Hemmelder M.H., de Graaf W., et al. Scintigraphic diagnosis of Erdheim-Chester disease. J Clin Oncol 2011, 29:e470-e472.
11. Haroche J., Amoura Z., Wechsler B., et al. Erdheim-Chester disease. Presse Med 2007, 36:1663-1668. [in French].
12. Andre M., Delevaux I., de Fraissinette B., et al. Two enlarged kidneys: a manifestation of Erdheim-Chester disease. Am J Nephrol 2001, 21:315-317.
13. Dion E., Graef C., Haroche J., et al. Imaging of thoracoabdominal involvement in Erdheim-Chester disease. AJR Am J Roentgenol 2004, 183:1253-1260.
14. Haroche J., Amoura Z., Trad S.G., et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006, 54:3330-3336.
15. Jeon I.S., Lee S.S., Lee M.K. Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer 2010, 55:745-747.
16. Tran T.A., Fabre M., Pariente D., et al. Erdheim-Chester disease in childhood: a challenging diagnosis and treatment. J Pediatr Hematol Oncol 2009, 31:782-786.
17. Arnaud L., Malek Z., Archambaud F., et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum 2009, 60:3128-3138.
18. Stenova E., Steno B., Povinec P., et al. FDG-PET in the Erdheim-Chester disease: its diagnostic and follow-up role. Rheumatol Int 2012, 32(3):675-678.
19. Dion E., Graef C., Miquel A., et al. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology 2006, 238:632-639.
20. Serratrice J., Granel B., De Roux C., et al. " Coated aorta" : a new sign of Erdheim-Chester disease. J Rheumatol 2000, 27:1550-1553.
21. Gupta A., Kelly B., McGuigan J.E. Erdheim-Chester disease with prominent pericardial involvement: clinical, radiologic, and histologic findings. Am J Med Sci 2002, 324:96-100.
22. Haroche J., Cluzel P., Toledano D., et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 2009, 119:e597-e598.
23. Fink M.G., Levinson D.J., Brown N.L., et al. Erdheim-Chester disease. Case report with autopsy findings. Arch Pathol Lab Med 1991, 115:619-623.
24. Loeffler A.G., Memoli V.A. Myocardial involvement in Erdheim-Chester disease. Arch Pathol Lab Med 2004, 128:682-685.
25. Kenn W., Stabler A., Zachoval R., et al. Erdheim-Chester disease: a case report and literature overview. Eur Radiol 1999, 9:153-158.
26. Alper M.G., Zimmerman L.E., Piana F.G. Orbital manifestations of Erdheim-Chester disease. Trans Am Ophthalmol Soc 1983, 81:64-85.
27. Sheidow T.G., Nicolle D.A., Heathcote J.G. Erdheim-Chester disease: two cases of orbital involvement. Eye (Lond) 2000, 14(Pt 4):606-612.
28. Khamseh M.E., Mollanai S., Hashemi F., et al. Erdheim-Chester syndrome, presenting as hypogonadotropic hypogonadism and diabetes insipidus. J Endocrinol Invest 2002, 25:727-729.
29. Tritos N.A., Weinrib S., Kaye T.B. Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis). J Intern Med 1998, 244:529-535.
30. Haroche J., Amoura Z., Touraine P., et al. Bilateral adrenal infiltration in Erdheim-Chester disease. Report of seven cases and literature review. J Clin Endocrinol Metab 2007, 92:2007-2012.
31. Opie K.M., Kaye J., Vinciullo C. Erdheim-Chester disease. Australas J Dermatol 2003, 44:194-198.
32. Droupy S., Attias D., Eschwege P., et al. Bilateral hydronephrosis in a patient with Erdheim-Chester disease. J Urol 1999, 162:2084-2085.
33. Arnaud L., Pierre I., Beigelman-Aubry C., et al. Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum 2010, 62:3504-3512.
34. Brun A.L., Touitou-Gottenberg D., Haroche J., et al. Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol 2010, 20:2579-2587.
35. Lachenal F., Cotton F., Desmurs-Clavel H., et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J Neurol 2006, 253:1267-1277.
36. Drier A., Haroche J., Savatovsky J., et al. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology 2010, 255:586-594.
37. Sheu S.Y., Wenzel R.R., Kersting C., et al. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol 2004, 57(11):1225-1228.
38. Provenzano E., Barter S.J., Wright P.A., et al. Erdheim-Chester disease presenting as bilateral clinically malignant breast masses. Am J Surg Pathol 2010, 34(4):584-588.
39. Johnson T.R., Lenhard M.S., Weidinger M., et al. An unusual breast tumor. Radiologe 2009, 49(10):942-945.
40. Haroche J., Cohen-Aubart F., Emile J.F., et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harbouring the BRAF V600E mutation. Blood 2013, 121:1495-1500.
41. Myra C., Sloper L., Tighe P.J., et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol 2004, 88:844-847.
42. Boissel N., Wechsler B., Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med 2001, 135:844-845.
43. Gaspar N., Boudou P., Haroche J., et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica 2006, 91:1121-1125.
44. Braiteh F., Boxrud C., Esmaeli B., et al. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 2005, 106:2992-2994.
45. Janku F., Amin H.M., Yang D., et al. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol 2010, 28:e633-e636.
46. Haroche J., Amoura Z., Charlotte F., et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008, 111:5413-5415.
47. Aouba A., Georgin-Lavialle S., Pagnoux C., et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010, 116:4070-4076.
48. Dagna L., Corti A., Langheim S., et al. Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012, 30(28):e286-e290.
49. Beeram M., Patnaik A., Rowinsky E.K. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005, 23(27):6771-6790.
50. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
51. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516.
52. Badalian-Very G., Vergilio J.A., Degar B.A., et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010, 116(11):1919-1923.
53. Haroche J., Charlotte F., Arnaud L., et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012, 120(13):2700-2703.
54. Emile J.F., Charlotte F., Amoura Z., et al. BRAF mutations in Erdheim-Chester disease. J Clin Oncol 2013, 31(3):398.
55. Dietrich S., Glimm H., Andrulis M., et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012, 366:2038-2040.
56. Stoppacciaro A., Ferrarini M., Salmaggi C., et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 2006, 54:4018-4022.
57. Dagna L., Girlanda S., Langheim S., et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford) 2010, 49:1203-1206.
58. Arnaud L., Gorochov G., Charlotte F., et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011, 117:2783-2790.